EASD 2022: Investigational Triple Agonist Shows Promise for Glycemic Control and Weight Loss in Type 2 Diabetes
Effects on body weight are particularly remarkable
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.